Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial

Katayoshi T, Uehata S, Nakashima N, Nakajo T, Kitajima N, Kageyama M · Scientific Reports

NULL on the vascular endpoint. Brachial-ankle pulse wave velocity fell by 25.1 ± 14.5 cm/s in the NMN group but the between-group difference was not significant (p=0.097). Serum nicotinamide rose significantly and the regimen was well tolerated.

Population

Healthy middle-aged adults

Intervention

NMN 125 mg twice daily (250 mg/day) for 12 weeks

Comparator

Placebo

Limitations

Seventeen to eighteen per arm — underpowered for a vascular endpoint. Conducted by a cosmetics and health-food manufacturer. The paper's own framing ('showed potential') runs ahead of a p of 0.097.